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Bacterial contamination of platelets for
transfusion: strategies for prevention
Jerrold H. Levy1*, Matthew D. Neal2 and Jay H. Herman3
Abstract
Platelet transfusions carry greater risks of infection, sepsis, and death than any other blood product, owing primarily
to bacterial contamination. Many patients may be at particular risk, including critically ill patients in the intensive
care unit. This narrative review provides an overview of the problem and an update on strategies for the prevention,
detection, and reduction/inactivation of bacterial contaminants in platelets. Bacterial contamination and septic
transfusion reactions are major sources of morbidity and mortality. Between 1:1000 and 1:2500 platelet units are
bacterially contaminated. The skin bacterial microflora is a primary source of contamination, and enteric contaminants
are rare but may be clinically devastating, while platelet storage conditions can support bacterial growth. Donor
selection, blood diversion, and hemovigilance are effective but have limitations. Biofilm-producing species can adhere
to biological and non-biological surfaces and evade detection. Primary bacterial culture testing of apheresis platelets is
in routine use in the US. Pathogen reduction/inactivation technologies compatible with platelets use ultraviolet light-
based mechanisms to target nucleic acids of contaminating bacteria and other pathogens. These methods have
demonstrated safety and efficacy and represent a proactive approach for inactivating contaminants before transfusion
to prevent transfusion-transmitted infections. One system, which combines ultraviolet A and amotosalen for broad-
spectrum pathogen inactivation, is approved in both the US and Europe. Current US Food and Drug Administration
recommendations advocate enhanced bacterial testing or pathogen reduction/inactivation strategies (or both) to
further improve platelet safety. Risks of bacterial contamination of platelets and transfusion-transmitted infections have
been significantly mitigated, but not eliminated, by improvements in prevention and detection strategies. Regulatory-
approved technologies for pathogen reduction/inactivation have further enhanced the safety of platelet transfusions.
Ongoing development of these technologies holds great promise.
Keywords: Bacterial contamination, Bacterial detection, Hemovigilance, Pathogen reduction/inactivation, Platelets,
Prevention strategies, Septic transfusion reaction (STR), Transfusion, Transfusion-transmitted bacterial infection (TTBI)
Background
The safety of allogeneic blood products has increased over
time because of significant improvements in donor
screening, testing, and deferrals [1]. Nonetheless, potential
risks of infection from viral, bacterial, and other pathogens
remain [1, 2]. Bacterial contamination of platelets is a
leading infectious risk of transfusion (Table 1 [3, 4]), and
platelet transfusions are associated with a greater risk of
sepsis and death than any other blood product [4]. The
US Food and Drug Administration (FDA) has issued draft
guidance recommending additional strategies to mitigate
bacterial contamination of platelet transfusions [4].
Platelet transfusions are common in critically ill inten-
sive care unit (ICU) patients [5], occurring in 9–30% of
patients [6]. Platelets are also commonly transfused in a
perioperative setting as either prophylaxis before surgery
or treatment for bleeding during or after surgery.
This narrative review provides an update on strategies.
We initially searched PubMed in December 2017 using the
primary search phrase “(bacteria OR bacterial) AND
(contamination OR contaminant) AND (platelet OR plate-
lets)”. This initial search returned 510 results. We also per-
formed searches with additional key terms (for example,
“prevention”, “detection”, “biofilm”, “hemovigilance”, “sur-
veillance”, “pathogen reduction”, and “pathogen inactiva-
tion”) to identify articles specifically relevant to each
section of this review. Only English language,
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peer-reviewed articles were considered; no constraints on
publication type or date were imposed. Titles/abstracts of
retrieved articles were checked for relevance, and other
relevant papers were identified by manual searching of ref-
erence lists and the authors’ personal literature collections.
Where multiple articles reported similar findings, priority
was given to those most recently published. In total, 70 arti-
cles were deemed by the authors as most relevant to the
topic of bacterially contaminated platelets intended for
transfusion and were included in this narrative review.
Bacterial contamination of platelets
Skin microflora is a principal source of bacterial contam-
ination. Furthermore, storage conditions—for example,
gas-permeable bags at room temperature (20–24 °C) with
continuous agitation—can effectively support bacterial
growth. A significant proportion of bacterial species that
contaminate platelets can form biofilms, multicellular ag-
gregations often encased in an extracellular matrix that
can adhere to biological and non-biological surfaces and
evade detection by culture screening systems that are
based on sampling of the supernatant [7]. Additionally, a
5-year study of over 2 million US platelet donations sug-
gested that the risk of bacterial contamination and sepsis
may be influenced by the type of plateletpheresis collec-
tion technology used [8, 9].
Transfusion-transmitted bacterial infection (TTBI) and
septic transfusion reactions (STRs) are major sources of
morbidity and mortality following platelet transfusion. In
the US, the therapeutic adult dose of platelets is a single
unit (that is, bag) which generally contains at least
3.0 × 1011 platelets [10]. The reported frequency of bacterial
contamination of platelets ranges from 1:1000 to
1:2500 units [2, 11–13]. Consideration of the per-patient—
rather than per-unit—risk provides visibility into the poten-
tial impact on patient outcomes. A review of four
large-scale independent studies showed that for a
hematology/oncology (H/O) patient receiving a mean of 6
apheresis platelet units per treatment episode, 1 out of 250
was at risk of receiving a contaminated platelet and 1 out of
1000 of having an STR [2]. In surgical patients, per-patient
risk may differ given the number of platelet units trans-
fused. Ning et al. observed a median of 1 platelet transfu-
sion (interquartile range of 1–2) per ICU patient admission
[14]. Greinacher and Selleng [15] noted that transfusion of
1 platelet unit is generally not sufficient for the thrombocy-
topenic ICU patient.
It has been acknowledged that TTBIs and STRs histor-
ically have been underreported [4]. The criteria used to
identify these events may impose limitations on recogni-
tion. According to AABB (formerly the American Associ-
ation of Blood Banks) and Centers for Disease Control
and Prevention (CDC) criteria, TTBI can be concluded
where no other potential confounding conditions exist, in-
fection manifests within 24 h of transfusion, and a positive
culture result is obtained from both patient samples and
transfusion bag. However, transfusion bags are typically
discarded after use and not available for culture, and pa-
tients on antibiotic therapy may not manifest positive
blood cultures, making the criteria ineffective. Further-
more, common transfusion reactions that are not usually
considered serious, such as febrile non-hemolytic transfu-
sion reactions, often are not documented. Only symptom-
atic TTBIs during transfusion are recorded [11], yet
infections may have variable times to manifest (that is,
post-transfusion), especially in seated prosthetic material.
For example, in a multistate US outbreak of Pseudomonas
fluorescens bacteremia traced back to contaminated hepa-
rinized saline intravenous flush syringes, 41% of patients
were diagnosed 84–421 days after the last potential expos-
ure to a contaminated saline flush syringe [16].
Several studies have shown that common hemovigilance
(HV) strategies—intended to collect, assess, and address
information on unexpected or undesirable effects of blood
products [17]—rarely detect TTBI-related morbidity and
mortality, particularly when passive surveillance is
employed. Passive surveillance relies on accurate and
timely reporting of suspected transfusion-associated ad-
verse reactions (often by untrained personnel) and can
lead to underreporting [11, 18]. Alternatively, active sur-
veillance strategies, which are not the standard for US HV,
use trained individuals to search for and identify adverse
reactions using standard definitions (sometimes with inde-
pendent adjudication), and sampling and testing of blood
products are carried out at the time of issue [11, 18].
Active surveillance, however, also has limitations, such as
the use of aerobic culture only and the absence of
methods addressing biofilm-forming organisms.
STRs are also underreported, as they may easily be
missed in neutropenic patients or those on antibiotic
therapy, because of passive surveillance strategies and
limitations of current detection methods. Narrow and
variable STR definitions which include fever and pos-
sibly other signs and symptoms (for example, rigors,
tachycardia, and dyspnea) also lead to underreporting
Table 1 Bacterial species identified in platelet concentrates and
implicated in transfusion-transmitted bacterial infections
Gram-positive Gram-negative
Bacillus speciesa Klebsiella species
Serratia speciesa
Streptococcus species Escherichia colia
Staphylococcus speciesa Acinetobacter species
Enterobacter species
Propionibacterium acnes Providencia rettgeri
Yersinia enterocolitica
aSome of which are biofilm-producing species
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[11], especially when clinical features mimic alternative
diagnoses [19]. In a retrospective study of over 50,000 plate-
let transfusions at a single large academic medical center,
20 out of 51,440 (0.04%, or 389 per million) platelet units
were identified by culture-based active surveillance as being
bacterially contaminated and resulted in five STRs, one of
which was fatal and none of which was reported by passive
surveillance to the hospital blood bank.
TTBIs and STRs can be life-threatening. The CDC re-
cently reported on three patient deaths due to transfu-
sion of bacterially contaminated platelets in Utah and
California [20], adding to others that have been reported
to the FDA [21]. In addition to the direct link between
contaminated platelets and TTBIs and STRs, data sug-
gest associations between platelet transfusion and bac-
terial infection incidence [5, 9].
Strategies to mitigate risk of bacterial contamination
Different strategies can be used to reduce the incidence
of bacterial infections and sepsis associated with platelet
transfusions. Transfusion medicine has traditionally re-
lied on methods designed to help avoid bacterial con-
tamination at the time of blood collection, processing,
and transfusion. The AABB’s Standards for Blood Banks
and Transfusion Services, the guidepost for blood collec-
tion, processing, and administration, require that
AABB-accredited facilities “have methods to limit and to
detect or inactivate bacteria in all platelet components”
[22]. These strategies are discussed below.
Prevention of bacterial contamination at time of platelet
collection
Donor selection is a first-line preventive measure and re-
lies on assessing possible bacterial infections by evaluating
the donor’s current medical conditions and antibiotic
treatment. The antecubital fossa of donors is inspected to
avoid venipuncture through scar tissue that might increase
contamination. Donors are asked about signs of infection
or illness. However, a survey of more than 11,000 donors
suggests that responses may vary depending on how ques-
tions are asked: affirmative responses regarding gastro-
intestinal symptoms (a risk factor for Yersinia species
contamination) were given by 0.6% or 4.0% of donors, de-
pending on which one of two questions were asked [23].
Questionnaires rely on accurate donor recollection and
symptom reporting, which may not always be sufficiently
reliable and cannot identify asymptomatic bacteremia.
Skin flora is a primary source of bacterial contamin-
ation, and needles used for venipuncture may generate a
small skin plug. Diversion of the initial blood volume (for
example, 10–20 mL) reduces bacterial contamination of
collected blood [24]. This procedure is effective in pre-
venting Gram-positive bacterial infections caused by the
skin bacterial microflora at the time of venipuncture.
Blood collection using a diversion pouch is a standard
practice to reduce contamination risk further [24].
Testing methods for platelet bacterial contamination
Culture-based
Until recently, using culture-based methods to detect bac-
teria within prespecified hours of platelet collection has
been the predominant method used by US blood collec-
tion establishments to comply with the AABB Standards
for Blood Banks and Transfusion Services [22]. However,
the sensitivity of primary bacterial culture screening is
only 22–40% [12, 13, 25], detecting between 1 and 10
colony-forming units per milliliter [26]. Furthermore, the
early sampling required to allow for microbial growth in a
culture-based system is at high risk of sampling error due
to the small starting number of contaminating bacteria in
a platelet donation, particularly for slow-growing species
[26]. Conventionally, culture-based detection methods
focus on aerobic species. As a result, anaerobic, faculta-
tive, and fastidious bacteria may go undetected, especially
when present at low concentrations. BacT/ALERT®(-
BioMérieux, Marcy-l’Étoile, France), which is FDA-ap-
proved for platelet quality control [26], is the primary
automated culture system used in the US today for plate-
let screening after collection. This system uses CO2 levels
to indicate bacterial growth and has been validated for de-
tection of bacterial contaminants [27, 28]. Screening pro-
grams for bacterial contamination of platelet units using
BacT/ALERT® have shown efficacy [29] and reduced the
incidence of TTBI [30]. The sensitivity of primary testing
with this system was improved when platelet sampling
was performed using a proportional sample volume (at
least 3.8% of the collection volume) rather than a fixed
sample volume; this may reduce sampling error and the
need for secondary testing [31]. A disadvantage of current
automated culture systems is that they may be ineffective
at detecting biofilm-producing organisms [32].
Secondary rapid detection methods
Other techniques target components of the bacterial cell
wall/membrane or intracellular molecules to detect
contaminating bacteria [26]. The BacTx® assay (Immu-
netics, Marlborough, MA, USA) detects bacterial peptido-
glycan through colorimetric measurements [33] and is
FDA-cleared for detecting bacterial contamination in
platelets. Analytical sensitivity of BacTx is 103 to 104 [26].
The Platelet Pan Genera Detection (PGD) Test (Verax
Biomedical, Marlborough, MA, USA), an immunoassay
that detects bacterial lipopolysaccharide and lipoteichoic
acid, has also demonstrated effectiveness [34, 35]. It is the
only test FDA-approved as a point-of-issue safety measure
in addition to a quality control test. Analytical sensitivities
of the Platelet PGD Test are 103 to 104 for Gram-positive
bacteria and 103 to 105 (some >106) for Gram-negative
Levy et al. Critical Care          (2018) 22:271 Page 3 of 8
bacteria [26]. The Platelet PGD Test is indicated for use
within 24 h of transfusion of the tested platelet unit.
When used with an appropriate FDA-approved platelet
collection, processing, and storage system, the Platelet
PGD Test can be used to extend platelet shelf life to 7 days
from 5 days by testing within 24 h of transfusion on day 6
or 7 (or both). Disadvantages of secondary rapid detection
methods include challenges with discordant results (false--
positive rate of 0.51%) [36] as well as time, labor, and in-
ventory management requirements associated with the
testing paradigm.
Pathogen reduction/inactivation technologies
In contrast to reactive screening and detection strategies,
newer technologies enable a proactive approach to redu-
cing contaminants in blood components and preventing
transfusion-transmitted infections. These technologies not
only target bacteria but also mitigate risks associated with
known and unknown viruses, parasites, protozoa, and leu-
kocytes. Although some authors view the cost of these
pathogen inactivation technologies as prohibitive [37, 38],
they can be cost-effective and comparable with other
blood safety interventions [39, 40] and are in universal ap-
plication for all platelet components in France,
Switzerland, and Belgium [41]. Recent developments for
the reduction or inactivation (or both) of pathogens in
blood products are based on using ultraviolet (UV) light.
Three pathogen reduction/inactivation technologies are
compatible with platelets (Table 2) [42–44]. Their mecha-
nisms of action differ by the wavelength of UV light used,
with concomitant differences in energy levels imparted:
with shorter wavelengths, energy level increases, as does
the potential to cause cellular damage (for example, to
platelets) (Fig. 1) [43].
INTERCEPT™ Blood System for Platelets
The INTERCEPT™ Blood System for Platelets (Cerus
Corporation, Concord, CA, USA) was first approved in
Europe in 2002, registered with a class III CE mark as a
medical device. It received FDA approval in 2014 for
apheresis platelets. INTERCEPT uses a combination of
UVA illumination and the photosensitive psoralen com-
pound amotosalen to achieve broad-spectrum pathogen
inactivation [45]. Amotosalen is added to the apheresis
platelet component and exposed to 3 J/cm2 UVA light
for 3–5 min, and residual amotosalen and photoprod-
ucts are removed using a compound adsorption device.
The process is typically performed at a blood collection
facility within 24 h of platelet donation.
Psoralens are found naturally in some foods and have
an affinity for nucleic acids. Amotosalen is a synthetic
psoralen that intercalates into DNA and RNA. It forms
Table 2 Overview of pathogen reduction/inactivation technologies compatible with platelet concentrates
INTERCEPT™ Blood System for Platelets Mirasol® Pathogen Reduction Technology
System
THERAFLEX® UV-Platelets
Manufacturer Cerus Corporation Terumo BCT MacoPharma
FDA approval
for platelets
Yes No No
CE mark approval CE class III CE class IIB CE class IIB
Principle
of method
UVA illumination in the presence
of a photosensitizer
Broad-spectrum UV illumination in
the presence of a photosensitizer
UVC illumination and intense
platelet bag agitation
Photosensitizer Amotosalen Riboflavin None
UV wavelength and
dose
UVA, 320–400 nm, 3 J/cm2 UVB/UVA/UVC (100%/60%/20%),
265–370 nm, 6.2 J/mL
UVC, 254 nm, 0.2–0.3 J/cm2
Pathogens
targeted
Bacteria (Gram-positive and Gram-negative),
viruses (enveloped and non-enveloped),
parasites
Bacteria (Gram-positive and Gram-negative),
viruses (enveloped and non-enveloped),
parasites
Bacteria (Gram-positive and
Gram-negative), viruses (enveloped
and non-enveloped), parasites
Toxicology
testinga
Acute toxicology, carcinogenicity,
general pharmacology, genotoxicity,
phototoxicity, repeated dose, reproductive
toxicology (plus others)
Acute toxicology, genotoxicity, phototoxicity,
repeated dose, reproductive toxicology
(plus others)
Not applicable (no exogenous
photosensitizer)
Bacterial inactivation (log reduction)b
Gram-positive 3.6 to >6.9 1.9 to 4.8 4.3 to >4.9
Gram-negative 4.5 to >6.7 2.8 to 5.4 >4.0 to >4.9
Maximum
approved storagec
5 and 7 days 7 days 5 days
Abbreviations: CE Conformité Européene (“European Conformity”), FDA US Food and Drug Administration, UV ultraviolet
aSee [43, 44] for additional details
bSee [43, 44] for data on individual bacterial species tested
cDepending on country
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strong covalent bonds only after UVA light, resulting in
formation of monoadducts and cross-linking of DNA and
RNA [45] and irreversibly blocking replication and repair.
This reaction occurs in an oxygen-independent manner.
Amotosalen was selected for its activity against a wide
range of bacteria (Gram-positive and Gram-negative) and
viruses (enveloped and non-enveloped) [46, 47] without
compromising platelet function. It passes through cellular
membranes, bacterial walls, and viral envelopes but cru-
cially does not interact with other cellular components
[45]; therefore, the functional characteristics of blood
components are maintained. Amotosalen also has activity
against residual leukocytes, helping to reduce risk of
transfusion-associated graft-versus-host disease and infec-
tion with intracellular pathogens such as cytomegalovirus
and Epstein–Barr virus for which leukocytes are a natural
reservoir. Treatment of platelet concentrates with INTER-
CEPT technology therefore reduces, and may replace, the
need for cytomegalovirus serology, bacterial detection,
and gamma irradiation. The clinical indications for
INTERCEPT-treated platelets remain the same as for con-
ventional platelet concentrates.
The safety and efficacy of platelets treated with INTER-
CEPT before transfusion have been demonstrated in mul-
tiple studies [48–50]. A 7-year, multinational, prospective,
HV study (19,175 INTERCEPT-treated platelet transfu-
sions in 4067 patients) found a low rate of acute transfu-
sion reactions and a safety profile consistent with that
previously reported for conventional platelet components
[51]. Combined national HV data from France and
Switzerland showed that 310,362 INTERCEPT-treated
platelet transfusions were associated with no septic reac-
tions or deaths, whereas about 2.5 million conventional
(untreated) platelet transfusions led to 62 STRs and 11
deaths [4]. In a US phase III clinical trial, INTERCEPT-
treated platelets met the primary endpoint of
non-inferiority for the incidence of grade 2 bleeding when
compared with conventional platelets [52]. A retrospective
comparative effectiveness study in about 1700 patients
found that pathogen inactivation with amotosalen and
UVA illumination did not significantly affect blood prod-
uct utilization or the efficacy and safety profile of platelet
transfusions in adult and pediatric patients (mostly cardiac
surgery and H/O patients) [53]. These findings show that
pathogen inactivation of platelet concentrates using amo-
tosalen and UVA illumination is compatible with the rou-
tine operations of a large tertiary care hospital.
Mirasol® Pathogen Reduction Technology System
The Mirasol® Pathogen Reduction Technology system
(Terumo BCT, Lakewood, CO, USA) is not
FDA-approved (starting phase III trials) but is approved in
selected markets, including some European countries.
Mirasol is also based on supplementation with a photo-
sensitive agent in combination with UV illumination, pri-
marily UVB, and relies heavily on the generation of
reactive oxygen species as the mechanism of action. This
process reduces pathogen load and inactivates residual
leukocytes. Rather than a synthetic psoralen, the Mirasol
system uses riboflavin, a naturally occurring vitamin (B2),
as a photosensitizer that promotes oxidation of nucleic
acids. In conjunction with broad-spectrum UV light (60%
of UVA, 100% of UVB, and 20% of UVC), this causes
nucleic acid chain modifications that are selectively tar-
geted to guanine bases [54]. The resulting damage to
DNA/RNA is irreversible because of the inhibition of rep-
lication and repair processes [54]. Administration of ribo-
flavin by multiple routes has been shown to be safe and
no new chemicals are introduced into the blood since the
photoproducts generated from its breakdown are physio-
logical metabolites that are present in human blood [54].
The Mirasol system is effective against a range of bac-
terial, viral, and parasitic infections [54, 55]. Treatment
with Mirasol demonstrated an overall effectiveness of 98%
against 20 clinically relevant bacterial strains when present
at very low bacterial concentrations characteristic of
Fig. 1 Wavelength, energy, and dose for pathogen reduction/inactivation technologies compatible with platelets. Irradiation doses for each
technology are 3 J/cm2 (INTERCEPT), 6.2 J/mL (Mirasol), and 0.2–0.3 J/cm2 (THERAFLEX)
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contamination at the time of collection; effectiveness was
91% at concentrations more typical for slow-growing bac-
teria at the timing of Mirasol treatment [55]. However,
biofilm-producing strains such as Staphylococcus epider-
midis may not be completely inactivated following ribofla-
vin/UV treatment of platelet concentrates [56]. Some
studies indicate preservation of platelet function following
Mirasol treatment [57] and no difference in the subse-
quent utilization of platelet and red blood cell products
relative to reference platelets [58]. Others have reported
significant effects of riboflavin/UV treatment on platelet
function, production of reactive oxygen species, and
oxidative damage [59, 60]. In a randomized controlled
trial of 118 patients with thrombocytopenia secondary
to chemotherapy, Mirasol-treated platelets exhibited a
safety profile comparable to reference platelets but
failed to meet noninferiority criteria based on corrected
count increment [58].
THERAFLEX® UV-Platelets
The THERAFLEX® UV-Platelets system (MacoPharma,
Mouvaux, France) is still undergoing clinical development
and is not currently licensed in any market. THERAFLEX
does not rely on supplementation of blood products with
a photoreactive agent. This system achieves pathogen re-
duction/inactivation using short-wave UVC illumination
alone. Targeted UVC irradiation (254 nm wavelength) in-
duces the formation of pyrimidine-based dimers and glo-
bal lesions within nucleic acid strands [61]. Illumination is
performed on both sides of the platelet bag and typically
requires less than one minute to achieve a biologically ac-
tive dose of UVC; this is coupled with intense agitation to
ensure uniform treatment [61]. The THERAFLEX system
is effective at inactivating a variety of bacterial and viral
species [61, 62], including emerging viruses [63]. Limited
effects of UVC treatment on platelet quality have been re-
ported [64], although the possible impact of the hard agi-
tation remains to be determined. A phase I study in
healthy individuals has shown that treated platelets are
well tolerated [65].
Potential limitations of mitigation strategies
Each strategy described above comes with unique limita-
tions, many of which are described above and summarized
here. Testing-based strategies are susceptible to sampling
errors, bacterial growth phase lag, aerobic versus anaer-
obic targeting, and biofilm detection, and they place re-
strictions on product availability and shelf life. This can
lead to fatal outcomes. Recently, two case reports
described three deaths due to bacterially contaminated
platelets. The authors stated that although all current pro-
cedures were followed, the risk of transfusion-transmitted
infections and fatality remains [20]. Pathogen reduction/
inactivation systems use different mechanisms and thus
show different bacterial inactivation results; no pathogen
reduction/inactivation system is effective against all patho-
gens. Furthermore, pathogen reduction is not currently
available for all platelet collections (for example, whole
blood-derived, 7-day), although development is ongoing.
Current guidance and future perspectives
Despite advances in strategies to address the risks asso-
ciated with platelet transfusions, the potential for bacter-
ial contamination remains. Recently, the FDA published
draft guidance for blood centers and transfusion services
on how to mitigate the risk of bacterial contamination of
platelets [4]. These recommendations focus on pathogen
reduction/inactivation technologies or bacterial testing
of platelets for transfusion. Both approaches reduced the
incidence of septic reactions associated with platelet
transfusions in a large, retrospective, international HV
study [41]. The AABB proposed that the FDA draft
guidance go further and mandate the routine implemen-
tation of enhanced, proactive, safety strategies using bac-
terial testing or pathogen reduction with FDA-approved
technologies [66], a view shared by others [67].
Although current pathogen reduction/inactivation tech-
nologies are effective against most bacterial contaminants
of platelets, they are not particularly effective against bac-
terial spores, and unknown and emerging pathogens are an
ongoing challenge with some technologies. Progress in
pathogen reduction/inactivation technologies continues, in-
cluding the clinical development of technologies for treat-
ing whole blood, red blood cells, and cryoprecipitate [68,
69]. Research efforts to further develop and validate tech-
nologies for pathogen reduction/inactivation and bacterial
detection will be aided by the recent enlargement of the
World Health Organization international repository for
platelet transfusion-relevant bacterial reference strains [70].
Minimizing risks associated with bacterially contaminated
platelets will require improvements in surveillance and
avoidance strategies to prevent contamination and, in de-
tection methods for identifying contaminated platelet units,
toward the ideal of readily available pathogen-safe platelets.
Conclusions
Bacterial contamination remains a substantial risk to pa-
tients requiring platelet transfusions. In addition to H/O
patients, critically ill and surgical patients may be at par-
ticular risk. Significant progress has been made to
minimize this risk, and further research and techno-
logical developments are ongoing. Historical avoidance
and screening strategies have reduced but not eliminated
the threat of transfusion-related bacterial infections. Re-
cent and future regulatory approval of technologies for
pathogen reduction and inactivation provides further
methods to reduce infections acquired through transfu-
sion of platelets.
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